Eupraxia PharmaceuticalsEPRX
13F holders, Q2 2025 (June 30)14holders +3
3new positions
0sold out
1famous investor
$5.53avg. 13F price*
At the end of Q2 2025, 14 institutions reported holding Eupraxia Pharmaceuticals Inc. (EPRX) in their 13F filings, up 3 from Q1 2025. 3 opened new positions and 0 sold out. The largest holders were Scotia Capital Inc. ($7.0M), Royal Bank of Canada ($2.5M) and Goldman Sachs Group Inc. ($229K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Eupraxia Pharmaceuticals Inc.
- CUSIP
- 29842P105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $362K |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 187,293 shares bought and 384,810 shares sold, net −197,517 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Scotia Capital Inc. | 0.03% | Reduce -16.8% | 1,291,989 | $7.0M |
| Royal Bank of Canada | 0.00% | Add +25.0% | 428,584 | $2.5M |
| Goldman Sachs Group Inc. | 0.00% | Add +15.4% | 39,800 | $229K |
| UBS Group AG | 0.00% | Reduce -26.8% | 37,499 | $216K |
| Bank of Montreal | 0.00% | Reduce -28.7% | 37,250 | $215K |
| Ingalls & Snyder LLC | 0.01% | New | 37,200 | $214K |
| Citadel Advisors | 0.00% | Add +51.3% | 18,236 | $108K |
| JPMorgan Chase & Co. | 0.00% | Add +593.2% | 18,717 | $108K |
| Cibc World Market Inc. | 0.00% | New | 15,000 | $86K |
| Bank of America Corp. | 0.00% | Add +402.4% | 12,559 | $72K |
| Raymond James Financial Inc. | 0.00% | Add +9.7% | 12,212 | $70K |
| Quadrature Capital Ltd | 0.00% | New | 10,700 | $61K |
| TD Waterhouse Canada Inc. | 0.00% | Reduce -90.9% | 9,600 | $56K |
| National Bank of Canada | 0.00% | Reduce -4.5% | 730 | $4K |
"% of holder's portfolio" is EPRX's weight in each manager's 13F, not the share of Eupraxia Pharmaceuticals Inc. the manager owns.